TriStar Health Partners

  • Home
  • About
    • TriStar
    • Team
  • News
  • Investment Strategy
    • Investment Strategy
    • Economic Development Fund – TN Investco
  • Portfolio
  • Contact

GenomOncology and med fusion announce the addition of PD-L1 Testing and Interpretation to the LungSEQ® and 50SEQ® Plus FISH Tests

March 9, 2017 By tstventures2015

med fusion, a Texas Oncology and The US Oncology Network preferred laboratory, and GenomOncology announce the expansion of med fusion’s LungSEQ® and 50SEQ® Plus FISH (for NSCLC) laboratory services to include PD-L1 expression testing. The panels will now help guide treatment selection of immunotherapeutic checkpoint inhibitors for metastatic non-small cell lung cancer (NSCLC). Read More

Filed Under: News

Our Portfolio


VIEW MORE

Subscribe to News & Events

Contact Us

Thank you for your interest in TriStar Health Partners. If you have questions or need further information, please contact us!

TriStar Health Partners

3322 West End Ave, Suite 1100 | Nashville, TN 37203
615.515-9880

Copyright © 2023 TriStar Technology Ventures. All rights reserved (CC-licensed photos excepted).